# Seredigm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seredigm

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Total disclosed funding: $8.5M
- Latest round: Series B (Dec 10, 2008)
- Investors on record: 7

## About

Based in Washington, US, Seredigm operates as a developer of tissue-protecting compositions.

## Funding rounds

- Series B, Dec 10, 2008, $0.8M — ARCH Venture Partners, OVP Venture Partners, Versant Ventures, Amgen Ventures, MPM BioImpact
- Series B, Jul 29, 2008, $0.7M — ARCH Venture Partners, OVP Venture Partners, Amgen Ventures, MPM BioImpact
- Series A, Mar 7, 2007, $2.5M — ARCH Venture Partners, OVP Venture Partners, Versant Ventures, Amgen Ventures, MPM BioImpact
- Series A, Jun 1, 2006, $4.5M — ARCH Venture Partners, OVP Venture Partners, Versant Ventures, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact, Accelerator Life Science Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- OVP Venture Partners (https://capitalatlas.ai/funds/ovp-venture-partners) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A